Health
J&J COVID-19 vaccine is 72% effective in the U.S., and 66% overall in large trial – Reuters
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will…
(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus.
FILE PHOTO: A vial and sryinge are seen in front of a displayed Johnson&Johnson logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from…
-
Business21 hours ago9 ASX shares including Nuix and PolyNovo dumped from ASX 200
-
Noosa News22 hours agoThree Bartender-Approved Peanut Butter Whisky Cocktails
-
Business21 hours agoGood rains mean this ASX 200 agricultural stock is tipped to deliver double-digit returns
-
Noosa News21 hours agoUnderstanding the conflict conundrum – Proctor